tetano
Editor, Senior Moderator
Int J Antimicrob Agents
. 2023 May 19;106857.
doi: 10.1016/j.ijantimicag.2023.106857. Online ahead of print. Prevalence of inappropriate use of nirmatrelvir-ritonavir antiviral therapy in hospitalized patients: A multicenter retrospective study in China
Changcheng Shi[SUP] 1 [/SUP], Lei Qiu[SUP] 2 [/SUP], Juanjuan Zhuo[SUP] 3 [/SUP], Yingying Fang[SUP] 4 [/SUP], Limin Wang[SUP] 5 [/SUP], Junbo Xia[SUP] 5 [/SUP], Shuying Wang[SUP] 6 [/SUP], Qing Luo[SUP] 7 [/SUP], Kang Zhou[SUP] 8 [/SUP], Yongchen Li[SUP] 9 [/SUP], Qingyu Li[SUP] 10 [/SUP], Gang Wang[SUP] 11 [/SUP], Nengming Lin[SUP] 12 [/SUP]
Affiliations
Background: Nirmatrelvir-ritonavir (NMVr) is a recently developed antiviral agent for treating coronavirus disease 2019 (COVID-19); however, data describing its appropriate use are scarce. This study examined the prevalence of inappropriate NMVr use in a Chinese hospital setting.
Methods: A multicenter retrospective chart review was performed for all hospitalized patients who received NMVr between December 15, 2022, and February 15, 2023, in the four university-affiliated hospitals in Hangzhou, China. A multidisciplinary team of experts developed the evaluation criteria. A group of senior clinical pharmacists examined and verified the suitability of NMVr prescriptions.
Results: A total of 247 patients received NMVr during the study period, of which 13.4% (n=31) met all the criteria for the appropriate use of NMVr. The leading types of inappropriate use of NMVr included delayed initiation of treatment (n=147, 59.5%), no dose adjustment for moderate renal impairment (n=46, 18.6%), use in severe-to-critical patients with COVID-19 (n=49, 19.8%), presence of contraindicated drug‒drug interactions with other medications (n=36, 14.6%), and prescriptions for patients without a confirmed diagnosis of COVID-19 (n=36, 14.6%).
Conclusions: The proportion of inappropriate use of NMVr was particularly high in the Chinese hospital setting, highlighting the urgent need to improve the appropriate use of NMVr.
Keywords: COVID-19; appropriate use; evaluation; nirmatrelvir-ritonavir.
. 2023 May 19;106857.
doi: 10.1016/j.ijantimicag.2023.106857. Online ahead of print. Prevalence of inappropriate use of nirmatrelvir-ritonavir antiviral therapy in hospitalized patients: A multicenter retrospective study in China
Changcheng Shi[SUP] 1 [/SUP], Lei Qiu[SUP] 2 [/SUP], Juanjuan Zhuo[SUP] 3 [/SUP], Yingying Fang[SUP] 4 [/SUP], Limin Wang[SUP] 5 [/SUP], Junbo Xia[SUP] 5 [/SUP], Shuying Wang[SUP] 6 [/SUP], Qing Luo[SUP] 7 [/SUP], Kang Zhou[SUP] 8 [/SUP], Yongchen Li[SUP] 9 [/SUP], Qingyu Li[SUP] 10 [/SUP], Gang Wang[SUP] 11 [/SUP], Nengming Lin[SUP] 12 [/SUP]
Affiliations
- PMID: 37211263
- DOI: 10.1016/j.ijantimicag.2023.106857
Background: Nirmatrelvir-ritonavir (NMVr) is a recently developed antiviral agent for treating coronavirus disease 2019 (COVID-19); however, data describing its appropriate use are scarce. This study examined the prevalence of inappropriate NMVr use in a Chinese hospital setting.
Methods: A multicenter retrospective chart review was performed for all hospitalized patients who received NMVr between December 15, 2022, and February 15, 2023, in the four university-affiliated hospitals in Hangzhou, China. A multidisciplinary team of experts developed the evaluation criteria. A group of senior clinical pharmacists examined and verified the suitability of NMVr prescriptions.
Results: A total of 247 patients received NMVr during the study period, of which 13.4% (n=31) met all the criteria for the appropriate use of NMVr. The leading types of inappropriate use of NMVr included delayed initiation of treatment (n=147, 59.5%), no dose adjustment for moderate renal impairment (n=46, 18.6%), use in severe-to-critical patients with COVID-19 (n=49, 19.8%), presence of contraindicated drug‒drug interactions with other medications (n=36, 14.6%), and prescriptions for patients without a confirmed diagnosis of COVID-19 (n=36, 14.6%).
Conclusions: The proportion of inappropriate use of NMVr was particularly high in the Chinese hospital setting, highlighting the urgent need to improve the appropriate use of NMVr.
Keywords: COVID-19; appropriate use; evaluation; nirmatrelvir-ritonavir.